1.82
price up icon4.60%   0.08
pre-market  Vorhandelsmarkt:  1.80   -0.02   -1.10%
loading
Schlusskurs vom Vortag:
$1.74
Offen:
$1.74
24-Stunden-Volumen:
30,159
Relative Volume:
0.01
Marktkapitalisierung:
$3.86M
Einnahmen:
$212.10K
Nettoeinkommen (Verlust:
$-40.19M
KGV:
-0.000343
EPS:
-5313.2836
Netto-Cashflow:
$-13.92M
1W Leistung:
+13.04%
1M Leistung:
-21.21%
6M Leistung:
-97.85%
1J Leistung:
-99.99%
1-Tages-Spanne:
Value
$1.73
$1.82
1-Wochen-Bereich:
Value
$1.62
$1.83
52-Wochen-Spanne:
Value
$1.51
$27,200.00

Aditxt Inc Stock (ADTX) Company Profile

Name
Firmenname
Aditxt Inc
Name
Telefon
909-488-0844
Name
Adresse
737 N. FIFTH STREET, SUITE 200, RICHMOND
Name
Mitarbeiter
26
Name
Twitter
Name
Nächster Verdiensttermin
2024-12-18
Name
Neueste SEC-Einreichungen
Name
ADTX's Discussions on Twitter

Vergleichen Sie ADTX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ADTX
Aditxt Inc
1.82 1.94M 212.10K -40.19M -13.92M -5,313.28
Biotechnology icon
ONC
Beigene Ltd Adr
238.76 24.41B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
434.03 111.55B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.2548 42.47M 0 0 0 0.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
596.85 63.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
VRNA
Verona Pharma Plc Adr
72.69 5.92B 0 -153.72M -103.81M -2.00

Aditxt Inc Aktie (ADTX) Neueste Nachrichten

pulisher
May 19, 2025

Aditxt (ADTX) Cancels Acquisition Agreement with Appili Therapeu - GuruFocus

May 19, 2025
pulisher
May 19, 2025

Aditxt Discusses Strategic Focus and Growth Plans - TipRanks

May 19, 2025
pulisher
May 19, 2025

Aditxt to Scrap Merger Deal With Appili Therapeutics - marketscreener.com

May 19, 2025
pulisher
May 19, 2025

Aditxt Announces Termination of Arrangement Agreement With Appili Therapeutics | ADTX Stock News - GuruFocus

May 19, 2025
pulisher
May 19, 2025

Aditxt Announces Termination Of Arrangement Agreement With Appili Therapeutics - marketscreener.com

May 19, 2025
pulisher
May 19, 2025

Appili Therapeutics Provides Update on Arrangement with Aditxt, Inc. - The Manila Times

May 19, 2025
pulisher
May 19, 2025

Aditxt Announces Termination of Arrangement Agreement With Appili Therapeutics - Business Wire

May 19, 2025
pulisher
May 15, 2025

Aditxt, Inc. SEC 10-Q Report - TradingView

May 15, 2025
pulisher
May 05, 2025

Aditxt Highlights Progress of ADI-100TM in Autoimmune Treatment - TipRanks

May 05, 2025
pulisher
May 02, 2025

Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, Chief Innovation Officer (CIO) of Aditxt™, and Dr. Friedrich Kapp, Co-CEO of Adimune™, to Discuss Progress of Lead Therapeutic Candidate ADI-100™ - Quantisnow

May 02, 2025
pulisher
May 02, 2025

Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, - GuruFocus

May 02, 2025
pulisher
Apr 28, 2025

Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department - GuruFocus

Apr 28, 2025
pulisher
Apr 26, 2025

Aditxt secures $256K through senior note sales By Investing.com - Investing.com Nigeria

Apr 26, 2025
pulisher
Apr 25, 2025

Aditxt secures $256K through senior note sales - Investing.com

Apr 25, 2025
pulisher
Apr 22, 2025

Aditxt’s Subsidiary Pearsanta Gets IRB Approval - TipRanks

Apr 22, 2025
pulisher
Apr 18, 2025

Aditxt Delivers Shareholder Update and 2024 Year-End Plan - ADVFN

Apr 18, 2025
pulisher
Apr 17, 2025

Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt's Subsidiary Adimune™ - Quantisnow

Apr 17, 2025
pulisher
Apr 17, 2025

Pre-market Movers: RGC, SYRS, ADTX, ATXI... - RTTNews

Apr 17, 2025
pulisher
Apr 17, 2025

Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt's Subsidiary Adim - GuruFocus

Apr 17, 2025
pulisher
Apr 17, 2025

Dr. Charles Howe of the Mayo Clinic’s Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt’s Subsidiary Adimune™ - Business Wire

Apr 17, 2025
pulisher
Apr 17, 2025

Dr. Charles Howe of the Mayo Clinic’s Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt’s Subsidiary Adimune - Bluefield Daily Telegraph

Apr 17, 2025
pulisher
Apr 16, 2025

Aditx Therapeutics Stock Hits 52-Week Low at $2.35 By Investing.com - Investing.com South Africa

Apr 16, 2025
pulisher
Apr 16, 2025

Aditx Therapeutics Stock Hits 52-Week Low at $2.35 - Investing.com Australia

Apr 16, 2025
pulisher
Apr 16, 2025

Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025 | ADTX Stock News - GuruFocus

Apr 16, 2025
pulisher
Apr 16, 2025

Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025 - Business Wire

Apr 16, 2025
pulisher
Apr 15, 2025

Aditxt (ADTX) Study Reinforces ADI-100's Promise in Autoimmune T - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Aditxt Subsidiary Adimune Announces Positive Results from Mayo C - GuruFocus

Apr 15, 2025
pulisher
Apr 14, 2025

Aditxt Regains Nasdaq Compliance with Bid Price - TipRanks

Apr 14, 2025
pulisher
Apr 14, 2025

Aditxt announces results from ADI-100 study - TipRanks

Apr 14, 2025
pulisher
Apr 14, 2025

Aditxt Subsidiary Adimune Announces Positive Results From Mayo Clinic Pre-Clinical Studies To Support FDA And European Regulatory Submissions For Type 1 Diabetes, Psoriasis, And Stiff Person Syndrome Human Trials - marketscreener.com

Apr 14, 2025
pulisher
Apr 14, 2025

Aditxt (ADTX) Study Reinforces ADI-100's Promise in Autoimmune Treatments | ADTX Stock News - GuruFocus

Apr 14, 2025
pulisher
Apr 14, 2025

Evofem Biosciences to Present at Emerging Growth Conference - Quantisnow

Apr 14, 2025
pulisher
Apr 14, 2025

Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials - Business Wire

Apr 14, 2025
pulisher
Apr 12, 2025

Rhythm Pharmaceuticals (RYTM): Surge in Interest Following Positive Trial Results | ADTX Stock News - GuruFocus

Apr 12, 2025
pulisher
Apr 12, 2025

Aditxt Weekly Update to Highlight Recent Events, Including Regaining Compliance with Nasdaq Listing Requirements | ADTX Stock News - GuruFocus

Apr 12, 2025
pulisher
Apr 11, 2025

ADITXT Earnings Preview: Recent $ADTX Insider Trading, Hedge Fund Activity, and More - Nasdaq

Apr 11, 2025
pulisher
Apr 11, 2025

Aditxt regains Nasdaq compliance, updates on operations By Investing.com - Investing.com India

Apr 11, 2025
pulisher
Apr 11, 2025

Aditxt Weekly Update to Highlight Recent Events, Including Regai - GuruFocus

Apr 11, 2025
pulisher
Apr 11, 2025

Aditxt regains Nasdaq compliance, updates on operations - Investing.com

Apr 11, 2025
pulisher
Apr 11, 2025

Aditxt Weekly Update to Highlight Recent Events, Including Regaining Compliance with Nasdaq Listing Requirements - Business Wire

Apr 11, 2025
pulisher
Apr 10, 2025

Why Aditxt Inc. (ADTX) Went Down On Thursday? - Insider Monkey

Apr 10, 2025
pulisher
Apr 10, 2025

Aditxt invests $1.5 million in Evofem amid merger talks By Investing.com - Investing.com Australia

Apr 10, 2025

Finanzdaten der Aditxt Inc-Aktie (ADTX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$581.44
price down icon 0.60%
$1.39
price up icon 6.92%
$32.50
price down icon 0.28%
$289.00
price down icon 1.22%
$4.2299
price up icon 5.48%
$72.69
price down icon 1.89%
Kapitalisierung:     |  Volumen (24h):